Entellus Medical Inc. (NASDAQ:ENTL)’s share price rose 4.1% on Friday . The stock traded as high as $19.65 and last traded at $19.52, with a volume of 70,194 shares. The stock had previously closed at $18.76.

ENTL has been the topic of several recent research reports. BTIG Research initiated coverage on shares of Entellus Medical in a research note on Tuesday, June 14th. They issued a “buy” rating and a $22.00 price objective on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $23.00 price objective on shares of Entellus Medical in a research note on Wednesday, June 29th. Bank of America Corp. reiterated a “buy” rating on shares of Entellus Medical in a research note on Monday, July 18th. Finally, Zacks Investment Research upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, August 8th. Six analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $23.00.

The company has a 50 day moving average price of $18.34 and a 200-day moving average price of $17.37. The stock’s market cap is $367.93 million.

Entellus Medical (NASDAQ:ENTL) last announced its earnings results on Wednesday, August 3rd. The medical technology company reported ($0.27) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.08. The firm earned $18.73 million during the quarter, compared to the consensus estimate of $18.48 million. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. The business’s revenue for the quarter was up 23.3% compared to the same quarter last year. On average, equities analysts forecast that Entellus Medical Inc. will post ($1.23) earnings per share for the current year.

In other news, VP Kevin L. Mensink sold 8,100 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $17.63, for a total transaction of $142,803.00. Following the sale, the vice president now owns 8,000 shares in the company, valued at $141,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brian E. Farley sold 17,006 shares of the business’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $19.33, for a total value of $328,725.98. Following the sale, the director now owns 560,265 shares in the company, valued at approximately $10,829,922.45. The disclosure for this sale can be found here.

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.